The 2021 Biosimilar Trends Report includes considerations for healthcare stakeholders on the potential for #biosimilars to lead to cost savings for healthcare systems, as well as provide additional treatment options and a greater degree of choice.

Across every therapeutic area of focus, Amgen’s efforts in manufacturing biologics, including biosimilars, come down to improving the lives of patients.

#Biosimilar growth is expected to continue, with competition in the U.S. estimated to triple by 2023. Amgen 🧪🔬🧬’s Jen Norton shares insights from Amgen’s 2021 Biosimilar Trends Report and how biosimilars can support the sustainability of the U.S. healthcare system.

On World Psoriasis Day, we’re proud to join IFPA in spreading awareness of the challenges faced by people living with psoriatic diseases, including moderate-to-severe plaque #psoriasis. #WPD2021 #UnitedNowAct

Competition between #biosimilars and their reference products and has the potential to provide additional cost savings for healthcare systems, while also helping guard against future health shocks such as pandemics. Learn more from Amgen 🧪🔬🧬’s Jen Norton:

We have a long-standing commitment to advancing biotechnology, which includes investments of more than two billion dollars across our portfolio of investigational and approved biosimilars.

Attending the 2021 World Biosimilar Congress EU? Don’t miss the panel discussion with Amgen 🧪🔬🧬’s Demet Gol, on key considerations for stakeholders to help drive #biosimilar uptake. If you’re unable to make the #FOB2021, check out Amgen’s 2021 Biosimilar Trends Report to learn more.

How can #biosimilars foster a resilient healthcare system? Amgen 🧪🔬🧬’s Greg Friberg will address this question and more at the 2021 World Biosimilar Congress EU. If you’re unable to attend, learn more about the promise of biosimilars from Amgen’s 2021 Trends Report. #FOB2021

Policymakers can support a sustainable, resilient marketplace with biosimilars by maintaining policies that allow competition among and between reference products and biosimilars.

As biosimilars expand into new therapeutic areas, educating patients about what #biosimilars are and the potential for costs savings will be crucial to encourage their utilization. Join Amgen 🧪🔬🧬’s Chad Pettit at @PatientAccess’ National Summit on Biologics to learn more.

This Lung Cancer Awareness Month, we’re showing support for patients living with #lungcancer. By investing in biologics, including biosimilars, we press on toward providing more treatment options for patients. #LCAM

With multiple #biosimilars approved in the U.S., we remain committed to our rich pipeline across multiple therapeutic areas. Ahead of the new year, we’re moving biosimilars content to Amgen 🧪🔬🧬 – allowing more people to discover biosimilars.

The rate of biosimilar uptake is generally increasing over time, with #biosimilars gaining significant share in the therapeutic areas where they have been introduced.

Regulatory authorities evaluate the “totality of evidence” to assess a biosimilar candidate.

Our #biosimilars and innovative biologics are manufactured using the same quality systems and good manufacturing practice (GMP) standards.

To build awareness of #biosimilars and their potential cost savings, we believe it takes all stakeholders – including physicians and their patients. That’s why it’s important to empower patients to take an active role in their treatment plan.

With more #biosimilars entering the U.S. biologics marketplace, it’s more important than ever to foster awareness and education about what they are, and how they impact the treatment of patients living with serious diseases.

Based on the significant savings created by competition with reference products and among biosimilars to date, we’re confident in the continued growth of the U.S. marketplace with #biosimilars, if competitive mechanisms remain in place.

With multiple #biosimilars approved in the U.S., we remain committed to our rich pipeline across multiple therapeutic areas. This week, we’re moving biosimilars content to Amgen 🧪🔬🧬 – allowing more people to discover Amgen information and resources on biosimilars.